Baidu
map

Oncogene:钙调素促进前列腺癌休眠

2020-12-31 AlexYang MedSci原创

前列腺癌是男性死亡的主要原因之一。前列腺癌患者死亡的主要原因可归结为疾病的转移扩散或初始治疗后的肿瘤复发。前列腺肿瘤发展成为局部或远处部位可见肿瘤之前,长期处于不能检测到或休眠状态。然而,休眠的分子机

前列腺癌是男性死亡的主要原因之一。前列腺癌患者死亡的主要原因可归结为疾病的转移扩散或初始治疗后的肿瘤复发。前列腺肿瘤发展成为局部或远处部位可见肿瘤之前,长期处于不能检测到或休眠状态。然而,休眠的分子机制尚不清楚

最近,有研究人员进行了基因表达差异分析,并发现了一个促进前列腺癌休眠的基因Regucalcin(RGN)。研究发现,RGN表达水平较高的癌症患者的无复发和总体生存期明显延长。利用多西环素诱导的RGN表达系统,研究人员发现RGN在前列腺肿瘤细胞中的异位表达诱导了体内休眠,而抑制RGN后则引发了肿瘤的复发生长。另一方面,在LNCap细胞中沉默RGN可促进其在小鼠胫骨中的外生长。重要的是,RGN促进多个已知的肿瘤休眠标记,包括p38 MAPK的激活、Erk信号的减少和FOXM1表达的抑制。此外,研究人员发现RGN通过增加外泌体中miR-23c分泌水平,能够显著抑制血管生成。有趣的是,他们发现FOXM1对前列腺癌中miR-23c的表达存在负调控。另外,研究人员还发现了11个RGN下游靶基因,它们能独立预测患者更长的无复发生存期,且这些基因的表达受到FOXM1和/或p38 MAPK的调控。

体内试验中RGN促进休眠

最后,研究人员指出,他们的发现表明RGN在前列腺癌休眠中发挥了关键作用,且RGN信号传导和外泌体miR-23c可作为预测复发的生物标志物

原始出处:

Sambad Sharma, Xinhong Pei, Fei Xing et al. Regucalcin promotes dormancy of prostate cancer. Oncogene. Dec 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1668070, encodeId=e16916680e005, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Sat May 01 19:56:44 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049353, encodeId=b88c20493539b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Aug 18 02:56:44 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913127, encodeId=be9691312e2d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Jan 02 19:10:38 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558209, encodeId=39a21558209a0, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Jan 02 05:56:44 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040916, encodeId=b92a1040916d7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 17:56:44 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2021-05-01 yese
  2. [GetPortalCommentsPageByObjectIdResponse(id=1668070, encodeId=e16916680e005, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Sat May 01 19:56:44 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049353, encodeId=b88c20493539b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Aug 18 02:56:44 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913127, encodeId=be9691312e2d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Jan 02 19:10:38 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558209, encodeId=39a21558209a0, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Jan 02 05:56:44 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040916, encodeId=b92a1040916d7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 17:56:44 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2021-08-18 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1668070, encodeId=e16916680e005, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Sat May 01 19:56:44 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049353, encodeId=b88c20493539b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Aug 18 02:56:44 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913127, encodeId=be9691312e2d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Jan 02 19:10:38 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558209, encodeId=39a21558209a0, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Jan 02 05:56:44 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040916, encodeId=b92a1040916d7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 17:56:44 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2021-01-02 ms3000000449926787

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1668070, encodeId=e16916680e005, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Sat May 01 19:56:44 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049353, encodeId=b88c20493539b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Aug 18 02:56:44 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913127, encodeId=be9691312e2d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Jan 02 19:10:38 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558209, encodeId=39a21558209a0, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Jan 02 05:56:44 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040916, encodeId=b92a1040916d7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 17:56:44 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2021-01-02 zsyan
  5. [GetPortalCommentsPageByObjectIdResponse(id=1668070, encodeId=e16916680e005, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Sat May 01 19:56:44 CST 2021, time=2021-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049353, encodeId=b88c20493539b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Wed Aug 18 02:56:44 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913127, encodeId=be9691312e2d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sat Jan 02 19:10:38 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558209, encodeId=39a21558209a0, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Sat Jan 02 05:56:44 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040916, encodeId=b92a1040916d7, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Dec 31 17:56:44 CST 2020, time=2020-12-31, status=1, ipAttribution=)]
    2020-12-31 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Eur Urol:传统疗法对前列腺导管癌治疗效果不佳

前列腺导管腺癌(DAC)是一种罕见的、侵袭性的和组织学变异的前列腺癌,用常规疗法治疗,类似于高风险前列腺癌(PAC)。最近,有研究人员评估了接受确定性治疗的DAC或高风险PAC男性的结果,并探索了雄激

Brit J Cancer:PTN可作为前列腺癌转移的生物标志物

从惰性前列腺癌(PC)中区分临床显著前列腺癌是一个重大的临床挑战。

Eur Urol:中、高风险前列腺癌根治性前列腺切除术中盆腔淋巴结切清扫的扩大与限制比较

扩大盆腔淋巴结切除术(EPLND)在前列腺癌(PCa)患者手术治疗中的作用仍存在争议,主要是因为缺乏随机对照试验(RCTs)。最近,有研究人员确定了是否EPLND与有限制的PLND(LPLND)有更好

Eur Urol:锕-225-PSMA-617在镥-177-PSMA治疗失败后的晚期转移性去势抵抗性前列腺癌中的活性和不良反应

β-放射Lu-177标记的前列腺特异性膜抗原(PSMA)放射配体治疗(RLT)是转移去势抵抗性前列腺癌(mCRPC)的新选择,但其抗肿瘤效果随时间推移而降低。最近,有研究人员报告了&alph

Br J Cancer:LIMK2介导的SPOP磷酸化降解促进去势抵抗性前列腺癌的发生发展

前列腺癌(PCa)目前仍是泌尿外科癌症中最普遍的类型,在美国,其在男性癌症相关死亡中排名第二。2020年美国约有191,930例新病例和33,330例预测死亡病例。尽管雄激素剥夺疗法可以有效治疗该疾病

Eur Urol:前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描成像对前列腺癌是否划算?

在将前列腺特异性膜抗原(PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)纳入常规护理之前,评估其效益是重要的。最近,有研究人员确定了PSMA-PET/CT与常规成像相比的效益情况。

Baidu
map
Baidu
map
Baidu
map